Actinium Pharmaceuticals presents new preclinical ATNM-400 data in prostate cancer, NSCLC at SNMMI 2026

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ATNM

0.00
  • Actinium Pharmaceuticals will present new preclinical updates on its Actinium-225 radiotherapy candidate ATNM-400 at the SNMMI 2026 meeting in Los Angeles.
  • Data are scheduled for May 31 and June 2, 2026, with posters highlighting activity in prostate cancer and non-small cell lung cancer models.
  • The work points to durable anti-tumor effects with a favorable safety profile versus selected standard-of-care comparators, supporting ATNM-400’s positioning as a mutation-agnostic approach.
  • A separate presentation will outline manufacturing and design optimization intended to improve tumor targeting, supporting the broader radioconjugate platform strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-062935), on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.